enVVeno Medical Corporation (NVNO)

5.0000 +0.0800 (+1.63%) As of 12:15PM EDT. Market open.

enVVeno Medical Corporation

70 Doppler
Irvine, CA 92618
United States
949 261 2900
https://www.envveno.com

Sector(s): Healthcare
Industry: Medical Devices
Full Time Employees: 31

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Robert A. Berman	CEO & Director	1.02M	N/A	1963
Mr. Craig Thomas Glynn	CFO, Treasurer & Secretary	313.69k	N/A	1961
Dr. Hamed Alavi Ph.D.	Senior VP & Chief Technology Officer	384.39k	N/A	N/A
Dr. Marc H. Glickman M.D.	Senior VP & Chief Medical Officer	491.59k	N/A	1949
Mr. Warren Hancock	Co-founder	N/A	N/A	N/A
Dr. Benedict Broennimann M.D.	Chief Medical Officer of Outside of United States	240k	N/A	1957
Mr. Andrew Cormack	Chief Commercial Officer	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of venous Chronic Venous Insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg; and enVVe, a non-surgical, transcatheter based replacement venous valve for the treatment of CVI. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

Corporate Governance

enVVeno Medical Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.